Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(20%)

Results Posted

67%(2 trials)

Phase Distribution

Ph phase_1

20%

Ph phase_4

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 4Post-market surveillance

3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(3)

Detailed Status

Completed3

Not yet recruiting1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (25.0%)

Phase 43 (75.0%)

Trials by Status

completed360%

not_yet_recruiting120%

recruiting120%

Recent Activity

1 active trials

Showing 5 of 5

recruitingphase_4

Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence

NCT01079988

Clinical Trials (5)

Showing 5 of 5 trials

NCT07341776Phase 4

Steroid Use in Treatment of Allergic Reactions to Food

Recruiting

NCT07328984Phase 4

How Long Should we Give Steroids for Patients With Severe PCP

Not Yet Recruiting

NCT07113834

Characteristics of Ankylosing Spondylitis Associated Uveitis

Completed

NCT02406651Phase 1

Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD

Completed

NCT01079988Phase 4

Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5